R. Lehner, Intelligent nanomaterials for medicine: Carrier platforms and 613 targeting strategies in the context of clinical application, Nanotechnology, vol.614, pp.742-57, 2013.

S. Marrache, Detouring of cisplatin to access mitochondrial genome for 616 overcoming resistance, Proc. Natl. Acad. Sci, vol.111, pp.10444-10453, 2014.

X. Sun, A pH-responsive yolk-like nanoplatform for tumor targeted dual-618 mode magnetic resonance imaging and chemotherapy, ACS Nano, vol.11, pp.7049-59, 2017.

S. Cajot, Design of reversibly core cross-linked micelles sensitive to 620 reductive environment, J. Control. Release, vol.152, pp.30-36, 2011.

N. Nishiyama and K. Kataoka, Current state, achievements, and future 622 prospects of polymeric micelles as nanocarriers for drug and gene delivery, 2006.

, Ther, vol.112, pp.630-678

C. Oerlemans, Polymeric micelles in anticancer therapy: Targeting, 625 imaging and triggered release, Pharm. Res, vol.27, pp.2569-89, 2010.

G. P. Stathopoulos and T. Boulikas, Lipoplatin formulation review article, J, vol.627, 2012.

, Drug Deliv, p.581363, 2012.

H. K. Patra and A. P. Turner, The potential legacy of cancer nanotechnology: 629 Cellular selection, Trends Biotechnol, vol.32, pp.21-31, 2014.

S. Li, Overcoming resistance to cisplatin by inhibition of glutathione S-631 transferases (GSTs) with ethacraplatin micelles in vitro and in vivo, Biomaterials, vol.144, pp.119-148, 2017.

S. Xu, Supramolecular cisplatin-vorinostat nanodrug for overcoming drug 634 resistance in cancer synergistic therapy, J. Control. Release, vol.266, pp.36-46, 2017.

M. T. Krauze, Real-time visualization and characterization of liposomal 636 delivery into the monkey brain by magnetic resonance imaging, Brain Res. Protoc, vol.16, p.637, 2005.

C. Zhang, Convection enhanced delivery of cisplatin-loaded brain 639 penetrating nanoparticles cures malignant glioma in rats, J. Control. Release, vol.263, pp.112-640, 2017.

H. Hillaireau and P. Couvreur, Nanocarriers' entry into the cell: Relevance to 645 drug delivery, Cell. Mol. Life Sci, vol.66, pp.2873-96, 2009.

L. Bregoli, Nanomedicine applied to translational oncology: A future 647 perspective on cancer treatment, Nanomedicine Nanotechnology, vol.12, p.81, 2016.

Y. Cai, Supramolecular "Trojan Horse" for nuclear delivery of dual 650 anticancer drugs, J. Am. Chem. Soc, vol.139, pp.2876-2885, 2017.

T. Boulikas, Clinical overview on Lipoplatin TM : A successful liposomal 652 formulation of cisplatin, Expert Opin. Investig. Drugs, vol.18, pp.1197-218, 2009.

A. A. Exner, Enhancement of carboplatin toxicity by Pluronic block 654 copolymers, J. Control. Release, vol.106, pp.188-97, 2005.

T. Yang, Anti-tumor efficiency of lipid-coated cisplatin nanoparticles co-656 loaded with microRNA-375, Theranostics, vol.6, pp.142-54, 2016.

J. F. Hainfeld, Gold nanoparticle imaging and radiotherapy of brain tumors 658 in mice, Nanomedicine, vol.8, pp.1601-1610, 2013.

J. R. Mccarthy and R. Weissleder, Multifunctional magnetic nanoparticles for 660 targeted imaging and therapy, Adv. Drug Deliv. Rev, vol.60, pp.1241-51, 2008.

H. Zhu, Responsive fluorescent Bi2O3@PVA hybrid nanogels for 662 temperature-sensing, dual-modal imaging, and drug delivery, Biomaterials, vol.33, p.3058, 2012.

Y. Cao, Photo-triggered fluorescent theranostic prodrugs as DNA 665 alkylating agents for mechlorethamine release and spatiotemporal monitoring, 2015.

, Biomol. Chem, vol.13, pp.6742-6750

Y. Yuan, Targeted theranostic platinum(IV) prodrug with a built-in 668 aggregation-induced emission light-up apoptosis sensor for noninvasive early 669 evaluation of its therapeutic responses in situ, J. Am. Chem. Soc, vol.136, pp.2546-54, 2014.

Y. M. Choi, Mechanism of cisplatin-induced cytotoxicity is correlated to 671 impaired metabolism due to mitochondrial ROS generation, PLoS One, vol.10, p.135083, 2015.

R. Mandal, Mass spectrometry study of hemoglobin-oxaliplatin complexes 673 in colorectal cancer patients and potential association with chemotherapeutic responses. heat shock proteins (HSP), in (8) the overexpression of markers of the epithelial to, DNA, vol.714, issue.10, p.716, 2006.

, Among other indications, cisplatin 720 provided a breakthrough in the management of testis cancer attributed to an intrinsic cellular 721 hypersensitivity together with a reduced ability to repair DNA adducts through the nucleotide 722 excision repair (NER) pathway [6]. Other molecular pathways are also involved in the 723 efficacy/toxicity of platinum-based regimen, DNA cross-linking recognition and reparation mechanisms allow for (12-a) a decreased 717 amount of DNA adducts, whereas, vol.16, p.726

, RT can increase the cellular uptake of 729 cisplatin and promote the activation of toxic Pt(II) complexes. Conversely, cisplatin may stop 730 the cell cycle and inhibit the molecular repair machinery that tackles radiation-induced DNA 731 damage, Innovative synergies capable of detouring drug resistance mechanisms. (1) Cisplatin is 727 conventionally used in combination with radiotherapy (RT) in the treatment of various solid 728 tumors as it enhances dose deposition, vol.28, p.737

, Advantages 739 of cisplatin nanovectorization over traditional regimens. Multifunctional nanocarriers are 740 developed and evaluated towards an optimized drug delivery to tumor cells for (1) 741 locoregional confinement in specific environments and/or for selective targeting of receptors 742